Earnings ·
Prothena Corporation reported second quarter 2026 financial results on August 6, 2026
PRTAProthena Corp Public Ltd Co
Prothena Corporation reported second quarter 2026 financial results on August 6, 2026. The company posted a net loss of $18.6 million for the quarter and net income of $14.1 million for the first six months, compared to losses in the prior year period. Total revenue was $1.0 million in Q2 and $52.1 million for the first half, driven by a $50.0 million milestone payment from Novo Nordisk and collaboration revenue from Bristol Myers Squibb. Cash and restricted cash stood at $289.1 million as of June 30, 2026. The company updated its full-year 2026 cash guidance to approximately $259 million, reflecting share repurchases. Prothena is a late-stage clinical biotechnology company focused on developing therapeutics for neurodegenerative and amyloid diseases.